Orthofix Medical Inc. (NASDAQ:OFIX) CEO Buys $125,400.00 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) CEO Massimo Calafiore acquired 10,000 shares of the stock in a transaction that occurred on Friday, May 9th. The stock was acquired at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the completion of the transaction, the chief executive officer now directly owns 234,603 shares in the company, valued at $2,941,921.62. This represents a 4.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Orthofix Medical Trading Down 0.5%

Shares of NASDAQ:OFIX traded down $0.06 during trading on Friday, reaching $12.14. 409,965 shares of the company were exchanged, compared to its average volume of 261,905. The firm has a market capitalization of $473.73 million, a PE ratio of -3.88 and a beta of 0.87. The business's fifty day simple moving average is $14.39 and its 200-day simple moving average is $16.78. Orthofix Medical Inc. has a 12-month low of $10.50 and a 12-month high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Institutional Investors Weigh In On Orthofix Medical

Institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of Orthofix Medical by 38.8% during the third quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock worth $1,912,000 after buying an additional 34,210 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Orthofix Medical by 480.7% during the third quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company's stock worth $1,318,000 after buying an additional 69,848 shares during the period. SG Americas Securities LLC raised its holdings in shares of Orthofix Medical by 24.3% during the fourth quarter. SG Americas Securities LLC now owns 21,279 shares of the medical device company's stock worth $372,000 after purchasing an additional 4,162 shares during the last quarter. Kirr Marbach & Co. LLC IN purchased a new position in shares of Orthofix Medical during the fourth quarter worth $532,000. Finally, R Squared Ltd purchased a new position in shares of Orthofix Medical during the fourth quarter worth $50,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OFIX. Roth Mkm reaffirmed a "buy" rating and issued a $22.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. StockNews.com downgraded shares of Orthofix Medical from a "buy" rating to a "hold" rating in a report on Wednesday, May 7th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $24.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.